Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Sprout’s Libido Pill Won’t Come Close To Viagra’s Impact

Written by: | news@biospace.com | Dated: Tuesday, August 18th, 2015

The FDA has approved a controversial drug designed to enhance a woman’s sexual drive. Addyi (generic name: flibanserin), from Sprout Pharmaceuticals, acts in the brain to enhance a woman’s libido. By taking one pill a day for a month, clinical trials showed that women on Addyi on average increased their number of satisfying sexual events by one a month from a baseline of 2 -3. That’s obviously not an enormous amount, but there is a subset of women for whom the drug had a better effect and, for them, the drug may prove to be of value. It was these data that led the FDA to approve Addyi.

Hey, check out all the research scientist jobs. Post your resume today!

Source: BioSpace Featured Stories

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom